Mizuho Securities Reiterates Buy Rating, $51 Price Target on Arcus Biosciences (RCUS), Believes Next Wave of Pipeline Assets is "Yet to Be Fully Incorporated into Valuation"
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $51.00 price target on Arcus Biosciences (NYSE: RCUS), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
